MPD
MCID: MYL031
MIFTS: 65

Myeloproliferative Neoplasm (MPD)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Myeloproliferative Neoplasm

MalaCards integrated aliases for Myeloproliferative Neoplasm:

Name: Myeloproliferative Neoplasm 12 58 54 6 15 37
Myeloproliferative Disorder 58 29 6 39 17
Chronic Myeloproliferative Disease 12 54 32
Chronic Myeloproliferative Disorder 17 71
Chronic Myeloproliferative Disorders 52
Myeloproliferative Disorders 54
Myeloproliferative Neoplasms 15
Myeloproliferative Disease 71
Campomelic Dysplasia 71
Cmpd, U 12
Cmpd 12
Mpd 58
Mpn 58

Characteristics:

Orphanet epidemiological data:

58
myeloproliferative neoplasm
Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:2226
NCIt 49 C4345
SNOMED-CT 67 20921005
ICD10 32 D47.1
MESH via Orphanet 44 D009196
UMLS via Orphanet 72 C0027022 C1292778
Orphanet 58 ORPHA98274
UMLS 71 C0027022 C1292778 C1861922

Summaries for Myeloproliferative Neoplasm

NIH Rare Diseases : 52 Chronic myeloproliferative disorders are a group of slow-growing blood cancers in which the bone marrow makes too many abnormal red blood cells , white blood cells , or platelets , which accumulate in the blood. The type of myeloproliferative disorder is based on whether too many red blood cells , white blood cells, or platelets are being made. Sometimes the body will make too many of more than one type of blood cell, but usually one type of blood cell is affected more than the others. There are 6 types of chronic myeloproliferative disorders: chronic myelogenous leukemia (CML), polycythemia vera , primary myelofibrosis (also called chronic idiopathic myelofibrosis), essential thrombocythemia , chronic neutrophilic leukemia , and chronic eosinophilic leukemia . Chronic myeloproliferative disorders sometimes become acute leukemia, in which too many abnormal white blood cells are made.

MalaCards based summary : Myeloproliferative Neoplasm, also known as myeloproliferative disorder, is related to myelodysplastic/myeloproliferative neoplasm and myeloproliferative disorder, chronic, with eosinophilia, and has symptoms including respiratory distress and apnea. An important gene associated with Myeloproliferative Neoplasm is MPL (MPL Proto-Oncogene, Thrombopoietin Receptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nutrients and Trace Elements have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A myeloid neoplasm that is characterized by a group of slow growing blood cancers in which large numbers of abnormal red blood cells, white blood cells, or platelets grow and spread in the bone marrow and the peripheral blood.

Wikipedia : 74 The myeloproliferative neoplasms (MPNs), previously myeloproliferative diseases (MPDs), are a group of... more...

Related Diseases for Myeloproliferative Neoplasm

Diseases related to Myeloproliferative Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 536)
# Related Disease Score Top Affiliating Genes
1 myelodysplastic/myeloproliferative neoplasm 34.8 STAT5B STAT5A PTPN11 PDGFRB NF1 JAK2
2 myeloproliferative disorder, chronic, with eosinophilia 33.9 PDGFRB ETV6
3 essential thrombocythemia 33.8 THPO STAT5B STAT5A PTPN11 MPL KIT
4 chronic neutrophilic leukemia 33.5 JAK2 CSF3R ABL1
5 polycythemia vera 33.4 THPO STAT5B STAT5A PTPN11 PDGFRB PDGFRA
6 myelofibrosis 33.4 THPO STAT5B STAT5A PDGFRB MPL KIT
7 atypical chronic myeloid leukemia 33.4 PDGFRB PDGFRA JAK2 FGFR1 ETV6 CSF3R
8 juvenile myelomonocytic leukemia 33.2 STAT5A PTPN11 PDGFRB PDGFRA NF1 JAK3
9 polycythemia 32.7 THPO STAT5B STAT5A MPL JAK3 JAK2
10 thrombocytosis 32.4 THPO STAT5B MPL JAK2
11 leukemia, chronic myeloid 32.3 THPO STAT5B STAT5A PTPN11 PDGFRB PDGFRA
12 hypereosinophilic syndrome 31.9 STAT5B PDGFRB PDGFRA KIT JAK2 FGFR1
13 myeloid leukemia 31.9 STAT5B STAT5A PTPN11 KIT JAK2 FLT3
14 budd-chiari syndrome 31.8 PDGFRA MPL JAK2
15 mastocytosis 31.8 STAT5B STAT5A PDGFRB PDGFRA KIT JAK2
16 systemic mastocytosis 31.7 STAT5B STAT5A PTPN11 PDGFRB PDGFRA KIT
17 lymphocytic leukemia 31.7 PTPN11 MIR155 ETV6 BCR ABL1
18 acute leukemia 31.7 THPO KIT JAK2 FLT3 ETV6 BCR
19 myelodysplastic syndrome 31.6 THPO STAT5B STAT5A PTPN11 PDGFRB NF1
20 thrombocytopenia 31.6 THPO PDGFRA MPL JAK2 ETV6
21 chronic myelomonocytic leukemia 31.6 PTPN11 PDGFRB PDGFRA NF1 MPL KIT
22 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 31.6 PDGFRB PDGFRA KIT JAK2 FGFR1 ETV6
23 neutropenia 31.4 THPO PTPN11 MPL CSF3R
24 chronic eosinophilic leukemia 31.4 STAT5B PDGFRB PDGFRA KIT JAK2 FLT3
25 leukemia 31.4 THPO PTPN11 NF1 MPL KIT JAK3
26 leukemia, acute myeloid 31.3 THPO STAT5B STAT5A PTPN11 PDGFRB PDGFRA
27 bone marrow cancer 31.2 THPO STAT5B STAT5A MPL MIR155 KIT
28 8p11 myeloproliferative syndrome 31.1 PDGFRB KIT FLT3 FGFR1 BCR
29 erythrocytosis, familial, 1 31.1 STAT5B STAT5A JAK2
30 leukemia, chronic lymphocytic 31.1 THPO STAT5B STAT5A PTPN11 MIR155 KIT
31 sarcoma 31.1 PDGFRB PDGFRA KIT JAK2 FGFR1
32 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 31.0 KIT FLT3 ETV6
33 acquired polycythemia 31.0 MPL JAK2
34 acute promyelocytic leukemia 31.0 STAT5B STAT5A FLT3 ETV6 CSF3R
35 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 31.0 PDGFRB PDGFRA FGFR1
36 hypereosinophilic syndrome, idiopathic 31.0 PDGFRB PDGFRA KIT
37 leukemia, acute lymphoblastic 3 31.0 PDGFRA FLT3 ETV6 BCR ABL1
38 neurofibromatosis, type iv, of riccardi 30.9 PTPN11 PDGFRA NF1 KIT
39 myeloma, multiple 30.8 STAT5B STAT5A PTPN11 MIR155 KIT JAK2
40 sm-ahnmd 30.8 PDGFRA KIT JAK2
41 leukemia, acute lymphoblastic 30.8 THPO STAT5B PTPN11 MPL MIR155 KIT
42 precursor t-cell acute lymphoblastic leukemia 30.8 FLT3 ETV6 BCR ABL1
43 severe combined immunodeficiency 30.7 STAT5B STAT5A KIT JAK3 FLT3
44 neutrophilia, hereditary 30.6 JAK2 FLT3 CSF3R
45 acute myeloblastic leukemia with maturation 30.6 KIT FLT3
46 brain cancer 30.6 PTPN11 PDGFRB PDGFRA NF1 ETV6
47 hematologic cancer 30.6 THPO STAT5B STAT5A PTPN11 PDGFRB MPL
48 lymphoma, non-hodgkin, familial 30.5 MIR155 JAK2 FLT3 FGFR1 ETV6 BCR
49 blood platelet disease 30.5 THPO MPL KIT JAK2 FLT3 ABL1
50 chronic leukemia 30.5 STAT5B STAT5A PDGFRB PDGFRA KIT JAK2

Graphical network of the top 20 diseases related to Myeloproliferative Neoplasm:



Diseases related to Myeloproliferative Neoplasm

Symptoms & Phenotypes for Myeloproliferative Neoplasm

UMLS symptoms related to Myeloproliferative Neoplasm:


respiratory distress, apnea

GenomeRNAi Phenotypes related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

26 (show top 50) (show all 51)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.84 BCR
2 Decreased viability GR00173-A 10.84 FLT3 PDGFRA
3 Decreased viability GR00221-A-1 10.84 ABL1 FGFR1 NF1 FLT3 PDGFRA PDGFRB
4 Decreased viability GR00221-A-2 10.84 ABL1 BCR FGFR1 JAK2 NF1
5 Decreased viability GR00221-A-3 10.84 ABL1 PDGFRA PDGFRB
6 Decreased viability GR00221-A-4 10.84 BCR NF1 FLT3 PDGFRA PDGFRB
7 Decreased viability GR00301-A 10.84 BCR KIT
8 Decreased viability GR00342-S-1 10.84 ABL1 PDGFRB
9 Decreased viability GR00342-S-2 10.84 ABL1
10 Decreased viability GR00342-S-3 10.84 ABL1 BCR
11 Decreased viability GR00402-S-2 10.84 ABL1 BCR FGFR1 JAK2 NF1 FLT3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.92 FGFR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.92 ETV6
14 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.92 MPL
15 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.92 FGFR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.92 FGFR1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.92 MPL
18 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.92 PDGFRA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.92 ETV6
20 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.92 STAT5A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.92 PDGFRA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.92 ETV6
23 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.92 STAT5A
24 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.92 ETV6
25 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.92 FGFR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.92 ETV6
27 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.92 MPL
28 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.92 FGFR1 STAT5A
29 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.92 STAT5A
30 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.92 ETV6
31 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.92 ETV6
32 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.92 PDGFRA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.92 MPL
34 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.92 FGFR1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.92 PDGFRA
36 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.92 STAT5A
37 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.92 FGFR1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.92 FGFR1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.92 PDGFRA
40 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.92 FGFR1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.92 ETV6
42 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.92 MPL
43 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.92 ETV6 FGFR1 MPL PDGFRA STAT5A
44 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.92 PDGFRA
45 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.92 FGFR1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.92 STAT5A
47 Decreased substrate adherent cell growth GR00193-A-1 9.87 KIT
48 Decreased substrate adherent cell growth GR00193-A-2 9.87 ABL1 KIT
49 Decreased substrate adherent cell growth GR00193-A-4 9.87 ABL1 FGFR1 FLT3 KIT
50 Increased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.35 ABL1 FGFR1 FLT3 JAK3 PDGFRB

MGI Mouse Phenotypes related to Myeloproliferative Neoplasm:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 ABL1 BCR CSF3R ETV6 FGFR1 FLT3
2 hematopoietic system MP:0005397 10.42 ABL1 BCR CSF3R ETV6 FGFR1 FLT3
3 immune system MP:0005387 10.39 ABL1 BCR CSF3R ETV6 FGFR1 FLT3
4 behavior/neurological MP:0005386 10.36 ABL1 BCR CSF3R FGFR1 JAK2 KIT
5 growth/size/body region MP:0005378 10.36 ABL1 BCR ETV6 FGFR1 FLT3 JAK2
6 homeostasis/metabolism MP:0005376 10.35 ABL1 BCR ETV6 FGFR1 FLT3 JAK2
7 endocrine/exocrine gland MP:0005379 10.34 ABL1 ETV6 FGFR1 FLT3 JAK2 JAK3
8 cardiovascular system MP:0005385 10.27 ABL1 ETV6 FGFR1 JAK2 JAK3 KIT
9 mortality/aging MP:0010768 10.27 ABL1 BCR CSF3R ETV6 FGFR1 FLT3
10 digestive/alimentary MP:0005381 10.25 ABL1 BCR ETV6 FGFR1 JAK3 KIT
11 embryo MP:0005380 10.24 ABL1 ETV6 FGFR1 JAK2 KIT MPL
12 integument MP:0010771 10.13 ETV6 FGFR1 JAK2 KIT NF1 PDGFRA
13 craniofacial MP:0005382 10.1 ABL1 FGFR1 KIT NF1 PDGFRA PDGFRB
14 normal MP:0002873 10.03 ABL1 BCR ETV6 FGFR1 JAK2 KIT
15 liver/biliary system MP:0005370 10.01 ABL1 BCR JAK2 KIT NF1 PTPN11
16 neoplasm MP:0002006 9.87 ETV6 FLT3 JAK2 KIT NF1 PDGFRA
17 reproductive system MP:0005389 9.61 FGFR1 JAK2 KIT NF1 PDGFRA PDGFRB
18 pigmentation MP:0001186 9.55 JAK3 KIT NF1 PDGFRA PTPN11
19 skeleton MP:0005390 9.28 ABL1 FGFR1 FLT3 JAK2 KIT NF1

Drugs & Therapeutics for Myeloproliferative Neoplasm

Drugs for Myeloproliferative Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 433)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Nutrients Phase 4
2 Trace Elements Phase 4
3 Micronutrients Phase 4
4 Liver Extracts Phase 4
5 Protein Kinase Inhibitors Phase 4
6 Imatinib Mesylate Phase 4 220127-57-1 123596
7
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
9
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
10
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
11
deoxycholic acid Approved Phase 3 83-44-3 222528
12
Hydroxyurea Approved Phase 3 127-07-1 3657
13
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
14
Perphenazine Approved Phase 3 58-39-9 4748
15
Baclofen Approved Phase 3 1134-47-0 2284
16
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
17
Amitriptyline Approved Phase 3 50-48-6 2160
18
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
20
Dalteparin Approved Phase 3 9005-49-6
21
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
22
Acyclovir Approved Phase 3 59277-89-3 2022
23
Histamine Approved, Investigational Phase 3 51-45-6 774
24
Hydroxyzine Approved Phase 3 68-88-2 3658
25
Thioguanine Approved Phase 3 154-42-7 2723601
26
tannic acid Approved Phase 3 1401-55-4
27
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
28
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
29
Sodium citrate Approved, Investigational Phase 3 68-04-2
30 Vedolizumab Approved Phase 3 943609-66-3
31
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
32
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
33
Anagrelide Approved Phase 3 68475-42-3 2182
34
Peginterferon alfa-2b Approved Phase 3 215647-85-1, 99210-65-8
35
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
36
Mycophenolic acid Approved Phase 3 24280-93-1 446541
37
Mercaptopurine Approved Phase 3 50-44-2 667490
38
Danazol Approved Phase 3 17230-88-5 28417
39
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
40
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
41
Polyestradiol phosphate Approved Phase 3 28014-46-2
42
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
43
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
44
Ponatinib Approved, Investigational Phase 3 943319-70-8 24826799
45
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
46
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
47
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
48
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
49 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
50 Antipruritics Phase 3

Interventional clinical trials:

(show top 50) (show all 628)
# Name Status NCT ID Phase Drugs
1 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
2 A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
3 Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
4 An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) Completed NCT01736540 Phase 4
5 Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib. Terminated NCT00461929 Phase 4
6 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
7 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
8 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
9 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
10 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
11 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
12 A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS Completed NCT00002742 Phase 3 amphotericin B deoxycholate;nystatin
13 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
14 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
15 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
16 A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell-Transfusion-Dependence Completed NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo;Pomalidomide
17 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
18 The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
19 A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
20 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
21 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
22 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
23 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
24 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
25 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
26 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
27 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
28 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
29 An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. Completed NCT02292446 Phase 3 Ruxolitinib
30 A Phase III Randomized, Multicenter, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythemia (TEAM-ET 2.0) Completed NCT02076815 Phase 3 Anagrelide retard;Thromboreductin
31 A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy Completed NCT00003600 Phase 3
32 Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation: The TRIST Study Completed NCT01237639 Phase 3
33 An Open-label, Single Arm, Phase III Study to Assess the Self-administration of AOP2014 Using a Pre-filled Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
34 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
35 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
36 A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201) Completed NCT00075816 Phase 3
37 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
38 A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
39 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
40 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
41 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
42 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes Completed NCT01381809 Phase 3 Group 2: Placebo;Group 1: Epoetin alfa
43 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
44 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
45 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
46 Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus. Recruiting NCT03808805 Phase 3 Aprepitant 80 mg;Hydroxyzine 25mg;Placebo of Hydroxyzine;Placebo of Aprepitant
47 PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant Recruiting NCT01366612 Phase 3 Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose);Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
48 A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials. Recruiting NCT04064060 Phase 3 Luspatercept
49 A Phase 3b, Multicenter, Single-arm, Open-label Safety AND Efficacy Study of Fedratinib in Subjects With DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Recruiting NCT03755518 Phase 3 FEDRATINIB
50 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03657160 Phase 3 Vedolizumab;Vedolizumab Placebo

Search NIH Clinical Center for Myeloproliferative Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Sodium phenylbutyrate

Genetic Tests for Myeloproliferative Neoplasm

Genetic tests related to Myeloproliferative Neoplasm:

# Genetic test Affiliating Genes
1 Myeloproliferative Disorder 29

Anatomical Context for Myeloproliferative Neoplasm

MalaCards organs/tissues related to Myeloproliferative Neoplasm:

40
Myeloid, Bone, Bone Marrow, T Cells, Neutrophil, Liver, B Cells

Publications for Myeloproliferative Neoplasm

Articles related to Myeloproliferative Neoplasm:

(show top 50) (show all 3282)
# Title Authors PMID Year
1
Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology. 6
23978506 2013
2
Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. 61 46
18299402 2008
3
Persistent localized bone marrow aplasia after radiotherapy with preserved peripheral counts: a study of 8 cases. 54 61
20471561 2010
4
Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. 54 61
20107158 2010
5
Triptolide inhibits Jak2 transcription and induces apoptosis in human myeloproliferative disorder cells bearing Jak2V617F through caspase-3-mediated cleavage of Mcl-1. 54 61
19942343 2010
6
Postsplenectomy sclerosing extramedullary hematopoietic tumor with unexpected good clinical evolution: morphologic, immunohistochemical, and molecular analysis of one case and review of the literature. 54 61
20042850 2010
7
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. 54 61
20130243 2010
8
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. 54 61
20008300 2010
9
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. 54 61
20061559 2010
10
CD72 negatively regulates KIT-mediated responses in human mast cells. 54 61
20100931 2010
11
JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. 54 61
19643476 2010
12
Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. 54 61
19996410 2010
13
Malignant diseases in Noonan syndrome and related disorders. 54 61
20029231 2009
14
JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN). 54 61
19625083 2009
15
The interferon consensus sequence binding protein (ICSBP/IRF8) activates transcription of the FANCF gene during myeloid differentiation. 54 61
19801548 2009
16
New GATA1 mutation in codon 2 leads to the earliest known premature stop codon in transient myeloproliferative disorder. 54 61
19850750 2009
17
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. 54 61
19727076 2009
18
Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant. 54 61
19682090 2009
19
Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. 54 61
19589925 2009
20
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. 54 61
19295546 2009
21
Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. 54 61
19394693 2009
22
An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. 54 61
19620628 2009
23
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. 54 61
19293402 2009
24
A novel JAK2 splicing mutation in neonatal myeloproliferative disorder accompanying congenital anomalies. 54 61
19344419 2009
25
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. 54 61
19273837 2009
26
Nf1 haploinsufficiency and Icsbp deficiency synergize in the development of leukemias. 54 61
19228926 2009
27
MPLW515L mutation in acute megakaryoblastic leukaemia. 54 61
19194467 2009
28
Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). 54 61
19006078 2009
29
CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis. 54 61
19960054 2009
30
[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant]. 54 61
19936007 2009
31
Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm. 54 61
19880761 2009
32
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation. 54 61
19174256 2009
33
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. 54 61
18927438 2009
34
Extramedullary peritoneal hematopoiesis combined with tuberculosis in a patient with primary myelofibrosis. 54 61
18850308 2009
35
Primary myelofibrosis: update on definition, pathogenesis, and treatment. 54 61
18947294 2009
36
Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. 54 61
18689547 2008
37
Human phenotypes associated with GATA-1 mutations. 54 61
18930124 2008
38
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. 54 61
18815196 2008
39
Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm. 54 61
18661406 2008
40
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 54 61
18669880 2008
41
Inhibitory effect of the substance P and its derivative on erythropoietin-independent growth of erythroid progenitors in polycythemia vera. 54 61
17980427 2008
42
Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. 54 61
18397343 2008
43
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. 54 61
18394555 2008
44
GATA1-related leukaemias. 54 61
18354416 2008
45
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. 54 61
17984312 2008
46
Stat5 as a diagnostic marker for leukemia. 54 61
18088232 2008
47
Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. 54 61
17693582 2007
48
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. 54 61
17654661 2007
49
Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. 54 61
17644747 2007
50
Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. 54 61
17394134 2007

Variations for Myeloproliferative Neoplasm

ClinVar genetic disease variations for Myeloproliferative Neoplasm:

6 (show all 11) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 JAK2 NM_004972.3(JAK2):c.1849G>T (p.Val617Phe)SNV Pathogenic 14662 rs77375493 9:5073770-5073770 9:5073770-5073770
2 MPL NM_005373.2(MPL):c.1514G>A (p.Ser505Asn)SNV Pathogenic/Likely pathogenic 14163 rs121913614 1:43814979-43814979 1:43349308-43349308
3 INSL6 , JAK2 NM_004972.3(JAK2):c.2047A>G (p.Arg683Gly)SNV Pathogenic/Likely pathogenic 375951 rs1057519721 9:5078360-5078360 9:5078360-5078360
4 JAK3 NM_000215.3(JAK3):c.1715C>T (p.Ala572Val)SNV Likely pathogenic 376037 rs121913504 19:17948009-17948009 19:17837200-17837200
5 KIT NM_000222.2(KIT):c.1675G>A (p.Val559Ile)SNV Likely pathogenic 376056 rs121913520 4:55593609-55593609 4:54727443-54727443
6 CSF1R NM_005211.3(CSF1R):c.1711T>G (p.Tyr571Asp)SNV Likely pathogenic 376166 rs1057519802 5:149441328-149441328 5:150061765-150061765
7 MPL NM_005373.2(MPL):c.1513A>T (p.Ser505Cys)SNV Likely pathogenic 376029 rs1057519752 1:43814978-43814978 1:43349307-43349307
8 INSL6 , JAK2 NM_004972.3(JAK2):c.2624C>A (p.Thr875Asn)SNV Likely pathogenic 376705 rs1057520016 9:5089726-5089726 9:5089726-5089726
9 INSL6 , JAK2 NM_004972.3(JAK2):c.1691G>T (p.Arg564Leu)SNV Likely pathogenic 376706 rs368927897 9:5072541-5072541 9:5072541-5072541
10 FGFR3 NM_000142.4(FGFR3):c.1118A>G (p.Tyr373Cys)SNV Conflicting interpretations of pathogenicity 16342 rs121913485 4:1806099-1806099 4:1804372-1804372
11 FGFR3 NM_000142.4(FGFR3):c.1657G>A (p.Val553Met)SNV Uncertain significance 376216 rs199544087 4:1807488-1807488 4:1805761-1805761

Copy number variations for Myeloproliferative Neoplasm from CNVD:

7 (show all 39)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 33241 1 43803475 43820135 Mutation MPL Myeloproliferative neoplasm
2 44192 10 53300000 71300000 Loss Myeloproliferative neoplasm
3 62279 12 107500000 132349534 Loss Myeloproliferative neoplasm
4 70916 12 66000000 69800000 Loss Myeloproliferative neoplasm
5 71420 12 69800000 91200000 Loss Myeloproliferative neoplasm
6 75262 13 18400000 31100000 Loss Myeloproliferative neoplasm
7 75265 13 18400000 72100000 Loss Myeloproliferative neoplasm
8 92698 15 42700000 55800000 Loss Myeloproliferative neoplasm
9 93011 15 47498995 47525965 Loss FGF7 Myeloproliferative neoplasm
10 106738 17 1 11200000 Loss Myeloproliferative neoplasm
11 108733 17 22200000 28800000 Loss Myeloproliferative neoplasm
12 109394 17 25800000 31800000 Deletion NF1 Myeloproliferative neoplasm
13 114437 17 47600000 54900000 Loss Myeloproliferative neoplasm
14 115165 17 55117687 55118542 Loss CLTC Myeloproliferative neoplasm
15 124069 19 1 19800000 Loss Myeloproliferative neoplasm
16 126326 19 18251575 18251854 Loss JUND Myeloproliferative neoplasm
17 127984 19 38473374 38495178 Loss CEBPA Myeloproliferative neoplasm
18 142294 2 221300000 230700000 Loss Myeloproliferative neoplasm
19 147392 2 64000000 83700000 Loss Myeloproliferative neoplasm
20 150691 20 40134805 41251971 Copy number PTPRT Myeloproliferative neoplasm
21 150692 20 41976905 42131668 Copy number TOX2 Myeloproliferative neoplasm
22 151958 20 27100000 62435964 Loss Myeloproliferative neoplasm
23 151974 20 27500000 63025520 Deletion L3MBTL Myeloproliferative neoplasm
24 158649 21 35044781 35543405 Loss RUNX1 Myeloproliferative neoplasm
25 164350 22 36286416 36295356 Translate CEP1 Myeloproliferative neoplasm
26 164841 22 39916010 39959748 Gain L3MBTL2 Myeloproliferative neoplasm
27 166129 3 1 8700000 Loss Myeloproliferative neoplasm
28 170893 3 161200000 184200000 Loss Myeloproliferative neoplasm
29 177254 3 54400000 71800000 Loss Myeloproliferative neoplasm
30 179193 3 8700000 30800000 Gain Myeloproliferative neoplasm
31 192210 5 108662279 108714138 Gain PJA2 Myeloproliferative neoplasm
32 196632 5 17000000 76400000 Loss Myeloproliferative neoplasm
33 199864 5 44387421 44399741 Loss FGF10 Myeloproliferative neoplasm
34 227798 7 7200000 19500000 Loss Myeloproliferative neoplasm
35 230718 8 1 12700000 Loss Myeloproliferative neoplasm
36 233709 8 12700000 19100000 Loss Myeloproliferative neoplasm
37 241221 8 59800000 106100000 Loss Myeloproliferative neoplasm
38 244938 9 1 49000000 LOH JAK2 Myeloproliferative neoplasm
39 246129 9 116700000 129300000 Loss Myeloproliferative neoplasm

Expression for Myeloproliferative Neoplasm

Search GEO for disease gene expression data for Myeloproliferative Neoplasm.

Pathways for Myeloproliferative Neoplasm

Pathways related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 STAT5B STAT5A PTPN11 PDGFRB PDGFRA NF1
2
Show member pathways
13.83 THPO STAT5B STAT5A PDGFRB PDGFRA NF1
3
Show member pathways
13.78 STAT5B STAT5A PTPN11 PDGFRB PDGFRA NF1
4
Show member pathways
13.77 THPO STAT5B STAT5A PDGFRB PDGFRA KIT
5
Show member pathways
13.69 THPO STAT5B STAT5A PDGFRB PDGFRA MPL
6
Show member pathways
13.58 PTPN11 PDGFRB PDGFRA NF1 KIT JAK3
7
Show member pathways
13.54 THPO STAT5B STAT5A PTPN11 PDGFRB PDGFRA
8
Show member pathways
13.42 THPO STAT5B STAT5A PDGFRB PDGFRA KIT
9
Show member pathways
13.37 THPO PTPN11 PDGFRB PDGFRA KIT JAK2
10
Show member pathways
13.26 STAT5B STAT5A PTPN11 PDGFRB PDGFRA NF1
11
Show member pathways
13.1 THPO PDGFRB PDGFRA KIT JAK2 FGFR1
12
Show member pathways
13.04 PDGFRB PDGFRA KIT JAK3 JAK2 FLT3
13
Show member pathways
12.99 STAT5B STAT5A PDGFRB PDGFRA JAK3 JAK2
14
Show member pathways
12.98 PDGFRB PDGFRA KIT FLT3 FGFR1
15 12.85 PDGFRB PDGFRA NF1 KIT FLT3 FGFR1
16
Show member pathways
12.85 THPO STAT5B STAT5A PTPN11 MPL JAK3
17
Show member pathways
12.78 PTPN11 PDGFRB PDGFRA KIT FGFR1
18
Show member pathways
12.76 PTPN11 PDGFRB PDGFRA NF1 KIT FLT3
19
Show member pathways
12.72 STAT5B STAT5A PDGFRB PDGFRA NF1 JAK3
20
Show member pathways